Specialty eye-care pharma selling Xdemvy, the first approved treatment for Demodex blepharitis (eyelid mite infection).
Specialty eye-care pharma selling Xdemvy, the first approved treatment for Demodex blepharitis (eyelid mite infection).
Revenue comes almost entirely from Xdemvy, a prescription eye drop approved in 2023, so uptake depends on eye doctors prescribing it and insurers paying for it. A pipeline in other eye and skin conditions is still at the trial stage.
Moat: narrow (IP / patents, regulatory licence). First and only approved Demodex blepharitis treatment, protected by patents and exclusivity.
Headquarters: Irvine, California, US · Founded: 2017 · Employees: 370
Size Tarsus Pharmaceuticals (TARS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.74B, the 1380th largest of 3,085 United States companies the cockpit tracks. Shares closed at $75.95 on 18 Nov 2026.
Performance Over six months the shares gained 17.2%, against +3.5% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 19 in its peer set.
Growth Revenue grew 86.3% over the last twelve months (peer median +10.3%); the operating margin is -9.6% (peer median 18.9%).
Valuation It trades at 5.2× enterprise value to sales against a peer median of 4.2× (7th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 35% a year for seven years (Req g). Recent delivered growth is +160%, so the hurdle is -125 pp: the price already allows for a slowdown.
Short interest Short interest is 12.3% of the free float (30 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $682M | $451M | $183M | $17.4M | $25.8M |
| Revenue growth | — | +147% | +949% | -32% | — |
| Gross profit | $636M | $421M | $170M | $15.9M | $24.9M |
| EBITDA | -$62.6M | -$69.2M | -$119M | -$142M | -$61.9M |
| Net income | -$702M | -$66.4M | -$116M | -$136M | -$62.1M |
| Free cash flow | $32.4M | -$22.3M | -$84.6M | -$119M | -$49.5M |
| Capital expenditure | $17.5M | $9.86M | $6.57M | $5.50M | $506,000 |
| Total debt | $88.7M | $83.0M | $72.5M | $31.7M | $20.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Tarsus Pharmaceuticals TARS | $3.74B | +17% | +86% | -10% | 5.2× | 34.7% |
| Bausch + Lomb BLCO.TO | $7.41B | +35% | +11% | 9% | 2.2× | 12.0% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 8.7× | -0.1% |
| Harrow HROW | $1.21B | +4% | +21% | 1% | 4.7× | n/a |
| Alcon ALC.SW | $36.9B | +18% | +1% | 12% | 3.9× | 12.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TARS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.9% | -0.2% | 6th highest of 21 |
| 6-month return | +17.2% | +3.5% | 7th highest of 19 |
| Distance from 52-week high | -17.0% | -26.4% | 8th highest of 21 |
| Revenue growth (TTM) | +86.3% | +10.3% | 3rd highest of 18 |
| Operating margin | -9.6% | 18.9% | 2nd lowest of 16 |
| EV / Sales | 5.2× | 4.2× | 7th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 34.7% | 3.0% | 4th most demanding of 13 |
| Growth delivered (Del g) | +159.5% | +6.7% | 2nd highest of 13 |
| Hurdle (Req g minus delivered) | -124.9 pp | -7.0 pp | 2nd least demanding of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | 5.2× | 34.7% | +159.5% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 4.2× | 1.2% | +12.1% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $3.75B | -10% | -13% | 20% | 5.1× | 16.2% | -5.8% |
| Livzon Pharmaceutical 000513.SZ | China | $3.76B | +4% | -14% | 19% | 2.3× | -9.6% | +2.7% |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 5.5× | 0.9% | +45.1% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 1.8× | -4.1% | -1.0% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 3.2× | 6.4% | +5.9% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 0.6× | -4.9% | +7.8% |
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | 27.6× | 57.4% | +3.1% |
| HanmiPharm 128940.KS | South Korea | $3.95B | -2% | +14% | 16% | 3.3× | 4.7% | +7.5% |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | 9.3× | 58.0% | +4.2% |
| Definium Therapeutics DFTX | United States | $3.99B | +40% | n/a | n/a | n/a | n/a | n/a |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 2.8× | n/a | n/a |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 20.4× | n/a | n/a |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $3.49B | -38% | +36% | -14% | 8.4× | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 6.6× | 49.2% | +367.3% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 3.1× | -2.1% | +12.0% |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |